FDA Adds Transparency On Paragraph IVs In Bid To Spur Competition

 
• By Aidan Fry

By disclosing when the first paragraph IV patent challenges were filed, how many players are in the race, and whether it has decided on eligibility for 180-day exclusivity, the FDA is aiming to spur greater competition in the US generics arena.

Jellyfish
The FDA is offering greater transparency on pargraph IV patent challenges is a bid to spur greater generic competition • Source: Shutterstock

More from Generics

More from Products